Anaptysbio (ANAB) Income towards Parent Company (2016 - 2026)
Anaptysbio (ANAB) posted Income towards Parent Company of -$52.9 million for Q1 2026, down 205.29% on a QoQ basis from $50.2 million in Q4 2025, and down 34.47% year-over-year from -$80.7 million in Q1 2025.
Anaptysbio (ANAB) Income towards Parent Company (2016 - 2026) Analysis & Trends
Anaptysbio's Income towards Parent Company history runs 11 years deep, the most recent figure standing at -$52.9 million for Q1 2026.
- Quarterly Income towards Parent Company fell 34.47% year-over-year to -$52.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.2 million (up 76.23% YoY) and the FY2025 annual result came in at -$12.6 million, up 89.0% from the prior year.
- Income towards Parent Company was -$52.9 million for Q1 2026 at Anaptysbio, down from $50.2 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $50.2 million in Q4 2025 and bottomed at -$62.6 million in Q1 2023.
- A 5-year average of -$31.2 million and a median of -$39.3 million in 2025 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2022 — Income towards Parent Company tumbled 94.94% — and 2025, when it soared 476.2%.
- Anaptysbio's Income towards Parent Company stood at -$22.7 million in 2022, then tumbled by 85.61% to -$42.2 million in 2023, then jumped by 120.67% to $8.7 million in 2024, then surged by 476.2% to $50.2 million in 2025, then plunged by 205.29% to -$52.9 million in 2026.
- Business Quant data shows ANAB's Income towards Parent Company at -$52.9 million in Q1 2026, $50.2 million in Q4 2025, and $15.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Anaptysbio | 1.55 Bn | 1.27 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.88 Mn |
| Dec 31, 2025 | 50.23 Mn |
| Sep 30, 2025 | 15.11 Mn |
| Jun 30, 2025 | -38.63 Mn |
| Mar 31, 2025 | -39.33 Mn |
| Dec 31, 2024 | 8.72 Mn |
| Sep 30, 2024 | -32.85 Mn |
| Jun 30, 2024 | -46.66 Mn |
| Mar 31, 2024 | -43.94 Mn |
| Dec 31, 2023 | -42.17 Mn |
| Sep 30, 2023 | -37.31 Mn |
| Jun 30, 2023 | -39.85 Mn |
| Mar 31, 2023 | -62.55 Mn |
| Dec 31, 2022 | -22.72 Mn |
| Sep 30, 2022 | -37.62 Mn |
| Jun 30, 2022 | -51.08 Mn |
| Mar 31, 2022 | -56.38 Mn |
| Dec 31, 2021 | -32.13 Mn |
| Sep 30, 2021 | -33.69 Mn |
| Jun 30, 2021 | -26.20 Mn |